Please use a PC Browser to access Register-Tadawul
Amalgam Announces Privia Health-Led Colorectal Cancer Screening Program Demonstrates 84% Screening Rates In 2024, Surpassing 80% Goal
Exact Sciences Corporation EXAS | 103.45 | +0.08% |
Privia Health Group, Inc. PRVA | 22.05 | -1.89% |
Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ:EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rates to 84% in 2024, exceeding national benchmarks and surpassing the National Colorectal Cancer Roundtable's 80% screening goal.


